Skip to content
lifestyle.infotechinc.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Mineralys Therapeutics, Inc.
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
May 25, 2026
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 24, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2026
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
May 23, 2026
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
May 22, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 26, 2026
←
Previous Page
1
2
3